The global clinical chemistry analyzers market is anticipated to reach USD 16 billion by 2025 growing at a healthy 5.5% CAGR over the forecast period (from 2014 to 2025). High prevalence of various chronic diseases is expected to positively affect the market as it considerably increases demand for clinical chemistry analyzers for better diagnosis.
In addition, awareness regarding the benefits of these devices is also expected to be a vital demand driver in the overall market. The introduction of highly advanced clinical chemistry analyzers has resulted in enhanced point-of-care (POC) testing capabilities. This has led to numerous opportunities for further market growth. These advancements include better resolution, modeling & parameter estimation, computer-assisted interpretation, artificial intelligence, and better pattern recognition.
The global clinical chemistry analyzers market is categorized as per products, tests, end use, and regions. On the basis of products, the categories are analyzers (small, large, medium, & others), reagents (standards, controls, calibrators & others), and others. Reagents held the largest demand share in 2015. This can be attributed to the availability of a wide range of reagents in the market. They differ as per the specific needs of clinicians. These reagents mainly include substrates, lipids, enzymes, electrolytes, and specific proteins that are essential for precise & accurate analytical procedures. Furthermore, reagents are considered highly cost-efficient and possess optimum sensitivity, precision, and linearity. These properties ensure reduced performance variation.
In-depth research report on global clinical chemistry analyzers market - http://www.grandviewresearch.com/industry-analysis/clinical-chemistry-analyzer-market
On the basis of tests, the market is divided into electrolyte panel, basic metabolic panel (BMP), liver panel, renal profile, lipid profile, specialty chemical tests, and thyroid function panel. The BMP segment accounted for a substantial share in the overall market in 2015. Rising occurrences of various lifestyle-induced disorders such as obesity and several other metabolic deformities are chief factors that propel this segment. Lipid profile is expected to grow at a lucrative CAGR over the forecast period. Growth of this segment is due to rising adoption rates owing to the need for screening tests for triglyceride & cholesterol levels in case of diabetes & cardiovascular disorders.
According end use, the clinical chemistry analyzers market is segregated into academic research centers, hospitals, diagnostic laboratories, and others. Hospitals dominated the end-use segment in 2016, as a result of high patient volume, large sample volumes, and frequent readmissions. Moreover, a well-developed healthcare infrastructure that facilitates successful diagnosis of illnesses resulted in the greater share of hospitals. The segment is further expected to grow rapidly as hospitals today are increasingly inclined toward getting fully automatic systems with integrated quality-assurance abilities and the capacity to process large quantities of samples.
Major players operating in the global clinical chemistry analyzers market are Thermo Fisher Scientific, Inc.; Siemens AG; F. Hoffmann-La Roche AG; and Johnson & Johnson. These companies often take to mergers & acquisitions, collaborative strategies, and development activities for manufacturing novel and highly developed products for a considerable market growth over a period of time.
The Pictus 700 by Diatron MI PLC is a small footprint, random access, and fully automatic floor clinical chemistry analyzer. The Pictus 700 uses Windows-based software for all its operations and is very sensitive with bar-coding for reagent & sample identification. The product also accepts several sizes of primary tubes. It can attain a total throughput of almost up to 780 tests every hour.